Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2008

View Archived Issues

Amgen presents results from a phase II study of AMG-108 in RA patients

Trial data show beneficial effects of epratuzumab in systemic lupus erythematosus

Atrasentan-liposomal doxorubicin combination feasible in platinum-resistant ovarian cancer

Nanocort safe in rheumatoid arthritis patients

ITF-2357 affects disease activity in systemic onset juvenile idiopathic arthritis

Esreboxetine improves pain, function and fatigue in double-blind fibromyalgia study

Athersys achieves development milestone in Bristol-Myers discovery alliance

Duska and DSM enter manufacturing collaboration for ATPace

Medtronic acquires CryoCath Technologies

Clinical data on CP-690550 in rheumatoid arthritis accumulates

AMG-623 characterized in phase I studies in systemic lupus erythematosus patients

FDA accepts TheraQuest's IND for abuse deterrent opioid TQ-1015

Novel compounds for lipoprotein disorders described in recent patents

Genetic Immunity doses first patient in phase II DermaVir Patch trial for HIV

Sygnis receives European orphan drug status for AX-200 in spinal cord injury

New antidiabetic agents disclosed in recent patent literature

GSK and Janssen patents divulge new therapeutics for GI disorders

Recent patent literature reports new oncolytic agents

Daiichi Sankyo commences phase III anti-influenza CS-8958 trial

FDA approves Banzel as adjunctive treatment for Lennox-Gastaut syndrome

Vernalis presents an update on clinical activities between July and November 2008

Third quarter highlights at AEterna Zentaris

Pfizer launches independent research unit Pfizer Regenerative Medicine

New glycine transporter GlyT1 inhibitor profiled at Merck & Co.

Merck Eprova imparts new PET imaging agents in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...